Overall Score

Base Case

OMER remains a cash-rich, clinically driven biotech with a current ratio of 1.95 and cash per share of 1.83, which supports near-term operating flexibility.

Valuation remains elevated on sales at 34.5x EV/Sales, but the market is still assigning value to the company’s earnings power with a 9.0x P/E and positive net income per share of 1.73.

Profitability is mixed: gross margin is very high at 95.8%, but operating profitability is still negative with operating margin at -189.5% and operating cash flow margin at -178.7%.

The balance sheet is manageable with net debt to EBITDA at 0.60x, but leverage and cash conversion remain noisy given negative equity and negative free cash flow yield.

Bull Case

If revenue scales without a proportional increase in R&D and SG&A, the company could convert its strong gross margin into durable operating leverage.

The low PEG ratio and positive earnings profile suggest upside if the market gains confidence in the sustainability of current profitability.

A stable liquidity position gives management room to fund pipeline execution without immediate financing pressure.

Bear Case

The biggest risk is that high gross margins do not translate into operating cash flow, as shown by negative operating cash flow and free cash flow metrics.

Valuation could compress sharply if earnings prove non-recurring or if the market re-rates the stock away from a 34.5x EV/Sales multiple.

Negative equity, weak interest coverage, and a long cash conversion cycle highlight ongoing financial and execution risk.